PMID- 26865445
OWN - NLM
STAT- MEDLINE
DCOM- 20161215
LR  - 20181202
IS  - 1969-6213 (Electronic)
IS  - 1774-024X (Linking)
VI  - 11
IP  - 11
DP  - 2016 Feb
TI  - Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent 
      thrombosis and mortality after percutaneous coronary intervention.
PG  - e1275-82
LID - EIJV11I11A249 [pii]
LID - 10.4244/EIJV11I11A249 [doi]
AB  - AIMS: We aimed to assess the association of bivalirudin with post-procedural 
      Thrombolysis In Myocardial Infarction (TIMI) flow, acute (</=24 hours) and 30-day 
      stent thrombosis (ST), and one-year mortality. METHODS AND RESULTS: The study 
      included 11,623 patients undergoing percutaneous coronary intervention (PCI). The 
      primary outcomes were post-procedural TIMI flow grade </=2 and definite acute ST. 
      In groups treated with bivalirudin (n=3,135), abciximab plus unfractionated 
      heparin (UFH; n=3,539) and UFH alone (n=4,949), post-procedural TIMI was </=2 in 
      5.2%, 3.2% and 3.2% of patients, respectively (adjusted odds ratio [OR]=1.96 [95% 
      confidence interval] 1.47-2.56 for bivalirudin versus abciximab plus UFH and 
      OR=1.56 [1.20-2.04] for bivalirudin versus UFH). Definite acute ST occurred in 
      two patients (0.06%) treated with bivalirudin, two patients (0.06%) treated with 
      abciximab plus UFH, and seven patients (0.14%) treated with UFH (p=0.47). 
      Bivalirudin was not associated with increased risk of 30-day ST (hazard ratio 
      [HR]=1.20 [0.59-2.43] versus abciximab plus UHF, and HR=0.93 [0.48-1.82] versus 
      UFH) or one-year mortality (HR=0.95 [0.70-1.28] versus abciximab plus UHF, and 
      HR=1.05 [0.78-1.41] versus UFH). CONCLUSIONS: Bivalirudin was associated with 
      higher risk of suboptimal post-PCI TIMI flow but not with increased risk of acute 
      or 30-day definite ST or one-year mortality compared with abciximab plus UFH or 
      UFH alone.
FAU - Fiedler, K Anette
AU  - Fiedler KA
AD  - Deutsches Herzzentrum, Technische Universitat, Munich, Germany.
FAU - Ndrepepa, Gjin
AU  - Ndrepepa G
FAU - Schulz, Stefanie
AU  - Schulz S
FAU - Floh, Simone
AU  - Floh S
FAU - Hoppmann, Petra
AU  - Hoppmann P
FAU - Kufner, Sebastian
AU  - Kufner S
FAU - Bernlochner, Isabell
AU  - Bernlochner I
FAU - Byrne, Robert A
AU  - Byrne RA
FAU - Schunkert, Heribert
AU  - Schunkert H
FAU - Laugwitz, Karl-Ludwig
AU  - Laugwitz KL
FAU - Kastrati, Adnan
AU  - Kastrati A
LA  - eng
PT  - Journal Article
PL  - France
TA  - EuroIntervention
JT  - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on 
      Interventional Cardiology of the European Society of Cardiology
JID - 101251040
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Anticoagulants)
RN  - 0 (Antithrombins)
RN  - 0 (Hirudins)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (Peptide Fragments)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Recombinant Proteins)
RN  - 9005-49-6 (Heparin)
RN  - TN9BEX005G (bivalirudin)
RN  - X85G7936GV (Abciximab)
SB  - IM
MH  - Abciximab
MH  - Aged
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Anticoagulants/therapeutic use
MH  - Antithrombins/*therapeutic use
MH  - Female
MH  - Heparin/therapeutic use
MH  - Hirudins
MH  - Humans
MH  - Immunoglobulin Fab Fragments/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/mortality/*therapy
MH  - Peptide Fragments/*therapeutic use
MH  - Percutaneous Coronary Intervention/methods/mortality
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Recombinant Proteins/therapeutic use
MH  - Risk
MH  - Stents
MH  - Thrombosis/*mortality
EDAT- 2016/02/13 06:00
MHDA- 2016/12/16 06:00
CRDT- 2016/02/12 06:00
PHST- 2016/02/12 06:00 [entrez]
PHST- 2016/02/13 06:00 [pubmed]
PHST- 2016/12/16 06:00 [medline]
AID - EIJV11I11A249 [pii]
AID - 10.4244/EIJV11I11A249 [doi]
PST - ppublish
SO  - EuroIntervention. 2016 Feb;11(11):e1275-82. doi: 10.4244/EIJV11I11A249.